PLATINUM INVESTMENT MANAGEMENT LTD
Position in SKYE — Skye Bioscience, Inc.
CIK 1256071
SYDNEY AUSTRALIA 2000, C3
Position in SKYE
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$20,200
+$2,293 QoQ
Shares Held
29,137
0.0% QoQ
Ownership
0.658%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#6
of 42 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SKYE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026PLATINUM INVESTMENT MANAGEMENT LTD holds $78,056,040 across 25 Biotechnology names. SKYE ranks #25 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | 58,314 | $7,740,017 | |||
| 2 | COGT |
Cogent Biosciences, Inc.
|
154,220 | $5,968,314 | |
| 3 | IMVT |
Immunovant, Inc.
|
144,671 | $5,574,173 | |
| 4 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
64,752 | $5,277,935 | |
| 5 | IDYA |
IDEAYA Biosciences, Inc.
|
138,708 | $5,169,647 | |
| 6 | VERA |
Vera Therapeutics, Inc.
|
113,687 | $4,878,309 | |
| 7 | GPCR |
Structure Therapeutics Inc.
|
90,363 | $4,849,782 | |
| 8 | RCUS |
Arcus Biosciences, Inc.
|
134,217 | $4,137,910 |
All Filings in SKYE
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $20,200 | 233,095 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $17,907 | 233,095 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $21,843 | 233,095 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $114,507 | 233,095 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $153,259 | 293,320 | Shares | Sole | 2025-07-21 | |
| 2025-03-31 | $58,297 | 293,320 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $153,543 | 434,046 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $237,141 | 485,199 | Shares | Sole | 2024-11-08 | |
| No filing history on record for this holder in this stock. | ||||||